Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05872984
Other study ID # NL71892.058.19
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 9, 2020
Est. completion date January 17, 2023

Study information

Verified date May 2023
Source HagaZiekenhuis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Establishing the euvolemic state in hemodialysis patients -the so called "dry weight"- is an important clinical conundrum in every nephrologist's daily practice. Underestimation of dry weight (with excessive ultrafiltration) results in dialysis-induced hypotension. Currently used methods to establish dry weight, including clinical assessment, bio-impedance spectroscopy and online relative blood volume (RBV) measurements, all have their limitations. RBV measurement reflects changes in blood volume during dialysis without providing any information about the initial hydration status, or the initial absolute blood volume (ABV). Recently, researchers proposed a new method to calculate ABV, by using the principle of dilution-indicator with RBV measurement. In a small cohort study they identified a total blood volume threshold of 65 millilitres per kilogram dry weight predicting for intra-dialytic hypotension associated symptoms. The goal of current clinical trial is to re-investigate the accuracy of the above-described method and to confirm the hypothesis of a critical threshold of 65 ml blood volume per kg dry weight in haemodialysis patients. Researchers will compare adjustment of dry weight based on the ABV measurement with standard care to see if dialysis-induced hypotension will be reduced.


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date January 17, 2023
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - hemodialysis patients of three dialysis locations of the Haga Hospital (Zoetermeer, The Hague Leyweg and The Hague Sportlaan). - Maintenance hemodialysis, with initiation of treatment predates inclusion in the study by at least 3 months. - Hemodialysis scheme three times weekly for four hours - Age above 18 years. Exclusion Criteria: - Clinically relevant fistula dysfunction resulting in single poold Kt/V <1,2 - Severe volume overload with a contraindication to bolus fluid infusion during dialysis according to the treating physician. - Severe cardiac dysfunction responsible for >1x intradialytic hypotension associated adverse event /week according to treating physician - Severe liver failure with or without presence of ascites - More than three hemodialysis sessions per week - Single needle treatment - Central venous access - Residual diuresis > 500 ml/ 24h - Inability to provide informed consent

Study Design


Intervention

Diagnostic Test:
adjustment of dry weight based on absolute blood volume measurement
adjustment of dry weight based on absolute blood volume measurement

Locations

Country Name City State
Netherlands HagaZiekenhuis Den Haag

Sponsors (1)

Lead Sponsor Collaborator
HagaZiekenhuis

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary difference in the incidence of intradialytic hypotension-associated adverse events between the intervention and control group The incidence of intradialytic hypotension-associated adverse events (IHAAE) will be compared at baseline and after intervention, using questionnaires. Participants will undergo a 4-week run-in period to assess baseline incidence. The incidence of IHAAE will be calculated by dividing the number of dialysis treatments with one or more symptoms attributable to IHAAE as a percentage of the total number of dialysis treatments with a completed questionnaire.
After randomization and the intervention, the occurence of IHAAE will be measured in both arms for another four weeks.
Differences in incidence of IHAAE between groups will be analyzed using ANCOVA, adjusting for baseline IHAAE, pre-dialysis blood pressure and the use of anti-hypertensive agents.
IHAAE is defined as a systolic blood pressure < 90 mmHg Either symptomatic or asymptomatic, or solely symptoms associated to (impeding) hypotension like dizziness, lightheadedness, sweating, cramps or visuel disturbances.
10 weeks
Secondary Baseline incidence of intradialytic hypotension associated adverse events (IHAAE) in the entire study population. Eligible participants will undergo a 4-week run-in period to assess baseline incidence of IHAAE, using questionnaires.
The incidence of IHAAE will be calculated by dividing the number of dialysis treatments with one or more symptoms attributable to IHAAE as a percentage of by the total number of dialysis treatments with a completed questionnaire.
baseline
Secondary Reproducibility of absolute blood volume measurement Absolute blood volume (ABV) will be measured twice in the entire study population, at the start of two mid-weekly hemodialysis treatments.
We will investigate the correlation between these two test results, using Bland Altman Analysis.
2 weeks
Secondary Correlation of absolute blood volume measurement with other diagnostic tests to determine blood volume We will calculate antropomorphic blood volume in the whole study population, using the Nadler's formula.
We will randomly select 10 participants for ABV measurement with the reference method.This technique is based on the isotope-dilution principal using I-251 radiolabeled human serum albumin. Adverse events due to the infusion of radioactive labelled albumin are very rare (0.01-0.1%, <0.01 % anaphylactic reactions). For a 70kg-patient the dose will be 0,02 millisievert. This falls within risk category I according to the International Commission on Radiological Protection (ICRP). This is the lowest risk category with a statistical probability of less than five in a million to develop radiation induced cancer. Annual background radiation level in the Netherlands is about 2,5 mSv.
We will correlate the results of these diagnostic tests to our ABV measurement, using Bland Altman analysis.
2 weeks
Secondary Sensitivity, specificity We will use the values of absolute volume measurement and incidence of IHAAE to calculate sensitivity, specificity of the previously defined critical threshold of normalized blood volume of 65 ml/kg for the occurrence of IHAAE. 10 weeks
Secondary positive predictive value, negative predictive value We will use the values of absolute volume measurement and incidence of IHAAE to calculate positive and negative predictive value of the previously defined critical threshold of normalized blood volume of 65 ml/kg for the occurrence of IHAAE. 10 weeks
See also
  Status Clinical Trial Phase
Completed NCT05980845 - The Effect Nature Sounds and Music on Hemodialysis Patients N/A
Recruiting NCT05020717 - Retrospective Survey of Hyperkalemia in Hemodialysis
Recruiting NCT04046042 - Virtual Reality Intradialysis: Last vs. First Part of the Session N/A
Recruiting NCT04094038 - The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients Phase 4
Completed NCT03311581 - The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery Phase 1
Completed NCT05531175 - REIKI APPLICATION PAIN, FATIGUE AND ITCHING IN HEMODIALYSIS PATIENTS N/A
Completed NCT04057313 - Coffee in Hemodialysis and Headache N/A
Completed NCT03061552 - Inferior Vena Cava Sonography in Hemodialysis Patients and Quality of Life N/A
Completed NCT03251573 - The Cohort Study of Cognitive Impairment in Chinese Hemodialysis Patients
Completed NCT05568342 - The Effect of Roy Adaptation-Based Nursing Intervention N/A
Completed NCT03527680 - Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins in Hemodialysis N/A
Completed NCT04063423 - Non- Clinical Coagulation Activation During Hemodialysis
Active, not recruiting NCT06203795 - Dialysis Performance of the FX CorAL Membrane N/A
Completed NCT04319328 - Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
Completed NCT03627884 - Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation Phase 4
Completed NCT05132036 - Lung Ultrasound Assessment of Fluid Overload in Haemodialysis Patients N/A
Completed NCT03076528 - An Innovative Virtually Supervised Exercise for Dialysis Patients Phase 2
Completed NCT06098443 - Acupressure Versus Transcutaneous Electrical Nerve Stimulation on Pain and Quality of Life Intradialysis N/A
Completed NCT04645121 - Carbon Monoxide-based Rebreathing Method and Bioimpedance in Hemodialysis Patients
Recruiting NCT04127877 - Bio Impedance-assisted Monitoring of Chronic Hemodialysis Patients N/A